Breakthroughs in the development of highly accurate fluid and neuroimaging biomarkers
have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional …

Neurological and psychiatric diseases have high degrees of genetic and pathophysiological
heterogeneity, irrespective of clinical manifestations. Traditional medical paradigms have …

Alzheimer's disease is the leading cause of dementia. However, neither Alzheimer's disease
nor Alzheimer's dementia are an inevitable consequence of aging. This review provides an …

Alzheimer disease (AD) is characterized by wide heterogeneity in cognitive and behavioural
syndromes, risk factors and pathophysiological mechanisms. Addressing this phenotypic …

Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

Although there is no unanimity, growing evidence supports the value of regular physical
exercise to prevent Alzheimer's disease as well as cognitive decline in affected patients …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Neuroinflammation commences decades before Alzheimer's disease (AD) clinical onset and
represents one of the earliest pathomechanistic alterations throughout the AD continuum …

Crop production stands as a pivotal pillar of global food security, but its sustainability faces
complex challenges from plant diseases, which pose a substantial threat to agricultural …

Alzheimer's disease (AD) is the most common cause of dementia, characterised by a
marked decline of both memory and cognition, along with pathophysiological hallmarks …